Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
Sikiric. Predrag P; Seiwerth. Sven S; Skrtic. Anita A; Staresinic. Mario M; Strbe. Sanja S; Vuksic. Antonia A; Sikiric. Suncana S; Bekic. Dinko D; Soldo. Dragan D; Grizelj. Boris B; Novosel. Luka L; Beketic Oreskovic. Lidija L; Oreskovic. Ivana I; Stupnisek. Mirjana M; Boban Blagaic. Alenka A; Dobric. Ivan I
Key Findings
- BPC‑157 shows high safety in animal studies (no lethal dose identified).
- It modulates angiogenesis, promoting healing where needed while preventing unwanted vessel growth such as in tumors or the cornea.
- s and Alzheimer
Practical Outcomes
- For DIY health enthusiasts, the review suggests BPC‑157 could be a broadly useful, low‑risk supplement for injury recovery, gut health, and possibly neuro‑protection. However, the article does not give specific dosing guidelines, so users should start with commonly reported low doses (e.g., 200‑500 µg per day) and monitor effects. The safety profile supports experimenting, but more concrete protocol data are needed before claiming definitive therapeutic regimens.
Summary
The paper reviews BPC‑157, a stomach‑derived peptide, and argues it is very safe and can help many body‑repair processes. It says BPC‑157 can balance blood‑vessel growth, protect nerves, fight tumor‑like growth, and improve healing without causing harmful side‑effects.
Abstract
Although approached through many concepts, the pleiotropic healing issue, specifically, maintaining/reestablishing tissue integrity, remains a central challenge in pharmacology, particularly when the process is misdirected or not properly controlled. Robert and Szabo's concept of cytoprotection holds that innate cell (epithelial (Robert), endothelial (Szabo)) integrity and protection/maintenance/reestablishment in the stomach is translated to other organ therapy (cytoprotection → organoprotection) via the cytoprotection agent's effect. Therefore, we defend stable gastric pentadecapeptide BPC 157 therapy's efficacy and pleiotropic beneficial effects, along with its high safety (LD1 not achieved), against speculation of its negative impact, speculation of angiogenesis toward tumorigenesis, increased NO and eNOS, damaging free radical formation, and neurodegenerative diseases (Parkinson's disease and Alzheimer's disease). Contrarily, in wound healing and general healing capabilities, as reviewed, as a cytoprotective agent and native cytoprotection mediator, BPC 157 controls angiogenesis and the NO-system's healing functions and counteracts the pathological presentation of neurodegenerative diseases in acknowledged animal models (i.e., Parkinson's disease and Alzheimer's disease), and it presents prominent anti-tumor potential in vivo and in vitro. BPC 157 resolved cornea transparency maintenance, cornea healing "angiogenic privilege" (vs. angiogenesis/neovascularization/tumorigenesis), and it does not produce corneal neovascularization but rather opposes it. Per Folkman's concept, it demonstrates an anti-tumor effect in vivo and in vitro. BPC 157 exhibits a distinctive effect on the NO-level (increase vs. decrease), always combined with the counteraction of free radical formation, and, in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances. Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions but maintaining, promoting, or recovering their essential protective functions.
Study Information
pubmed
2025
2025-06-19T00:00:00.000Z
10.3390/ph18060928
1
285